Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.

[en] SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive immunosuppression it should not be given to stable or non-progressing disease. The correct identification of disease with high risk of progression remains a challenge for early therapeutic intervention, and biomarkers remain urgently needed. In fact, eight categories of biomarkers have been identified and classified according to the different biological pathways involved. The purpose of this article is to describe the main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-interstitial lung disease.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

BONHOMME, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

ANDRE, Béatrice ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie

GESTER, Fanny ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

DE SENY, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie

MOERMANS, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Service de pneumologie - allergologie

Struman, Ingrid ; Université de Liège - ULiège > Cancer-Molecular Angiogenesis Laboratory

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

MALAISE, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie

GUIOT, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

Language :

English

Title :

Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.

Publication date :

2019

Journal title :

Rheumatology

ISSN :

1462-0324

eISSN :

1462-0332

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 12 October 2019

Statistics

Number of views

132 (12 by ULiège)

Number of downloads

84 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
Cappelli S, Randone SB, Camiciottoli G et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 2015;24:411-9.
Guiot J, Moermans C, Henket M, Corhay J-L, Louis R. Blood biomarkers in idiopathic pulmonary fibrosis. Lung 2017;195:273.
Njock M-S, Guiot J, Henket MA et al. Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax 2019;74:309-12.
Fastres A, Felice F, Roels E et al. The lung microbiome in idiopathic pulmonary fibrosis: a promising approach for targeted therapies. Int J Mol Sci 2017;18:2735.
Goh NSL, Desai SR, Veeraraghavan Set al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.
Duysinx B, Guiot J, Pellegrini I et al. Invasive diagnostic techniques for diffuse interstitial pneumopathies. Rev Med Liege 2018;73:147-55.
Guiot J, Bondue B, Henket M, Corhay JL, Louis R. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC Pulm Med 2016;16:86.
Didier K, Bolko L, Giusti D et al. Autoantibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol 2018;9:541.
Gester F, Duysinx B, Von Frenckell C, Louis R, Guiot J. Pattern of biological changes in interstitial lung diseases. Rev Med Liege 2019;74:47-53.
Kuroki Y, Takahashi H, Chiba H, Akino T. Surfactant proteins A and D: disease markers. Biochim Biophys Acta 1998;1408:334-45.
Mona E, Julio C, Pedroza, C, Liu, X et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol 2013;40:114-1120.
Asano Y, Ihn H, Yamane K et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001;44:1363-9.
Hant FN, Ludwicka-Bradley A, Wang H-J et al. Disease in patients with scleroderma surfactant protein D and KL-6 as serum biomarkers of interstitial lung. J Rheumatol 2009;3636:773-80.
Koichi Y, Minoru H, Kazuhiko T, Shinichi S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers of monitoring activity of pulmonary fibrosis. J Rheumatol 2004;31:1112-20.
Elhai M, Hoffmann-Vold AM, Avouac J et al. Performance of candidate serum biomarkers for systemic sclerosis-interstitial lung disease. Arthritis Rheumatol 2019;71:972-82.
Kumanovics G, MinierT, Radics J et al. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/poly-myositis. Clin Exp Rheumatol 2008;26:414-20.
Maeda M, Ichiki Y, Aoyama Y, Kitajima Y. Surfactant protein D (SP-D) and systemic scleroderma (SSc). J Dermatol 2001;28:467-74.
Kennedy B, Branagan P, Moloney F et al. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffus Lung Dis 2015;32:228-36.
Sumida H, Asano Y, Tamaki Z et al. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: a longitudinal observational study. J Dermatol 2018;45:1425-33.
Kuwana M, Shirai Y, Takeuchi T. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol 2016;43:1825-31.
Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000;200:196-201.
Oguz EO, Kucuksahin O, Turgay M et al. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study. Clin Rheumatol 2016;35:663-6.
Yanaba K, Hasegawa M, Hamaguchi Y et al. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003;21:429-36.
Doishita S, Inokuma S, Asashima H et al. Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases. Intern Med 2011;50:2889-92.
Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006;260:429-34.
Fukaya S, Oshima H, Kato K et al. KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases. Rheumatol Int 2000;19:223-5.
Hasegawa M, Asano Y, Endo H et al. Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. PLoS One 2014;9:e88150.
Tiev KP, Hua-Huy T, Kettaneh A et al. Serum CC chemo-kine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011;38:1355-60.
Schupp J, Becker M, Gunther J et al. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J 2014;43:1530-2.
Hoffmann-Vold AM, Tennøe AH, Garen T et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis. Chest 2016;150:299-306.
Giacomelli R, Afeltra A, Alunno A et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev 2019;18:93-106.
Wu M, Baron M, Pedroza C et al. CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts. Arthritis Rheumatol 2017;69:1871-8.
Hoffmann-Vold A, Huyen R, Volkmann ER et al. High level of chemokine CCL2 is associated with lung fibrosis progression and reduced survival in two independent systemic sclerosis cohort. Arthritis Rheumatol 2016;68. https://acrabstracts.org/abstract/high-level-of-chemoki-ne-ccl2-is-associated-with-lung-fibrosis-progression-and-reduced-survival-in-two-independent-systemic-sclerosis-cohorts/.
Hasegawa M, Fujimoto M, Matsushita T et al. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011;30:231-7.
De Lauretis A, Sestini P, Pantelidis P et al. Serum inter-leukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013;40:435-46.
Cossu M, van Bon L, Preti C et al. Earliest phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum. Arthritis Rheumatol 2017;69:2359-69.
Moinzadeh P, Krieg T, Hellmich M et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol 2011;20:770-3.
Manetti M, Guiducci S, Romano E et al. Increased serum levels and tissue expression of matrix met alloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012;71:1064-72.
Asano Y, Ihn H, Kubo M et al. Clinical significance of serum levels of matrix met alloproteinase-13 in patients with systemic sclerosis. Rheumatology (Oxford) 2006;45:303-7.
Young-Min SA, Beeton C, Laughton R et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 2001;60:846-51.
Kikuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K. Serum tissue inhibitor of met alloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 1995;33:973-8.
Mihai C, Tervaert J. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis 2010;69:319-24.
Ihn H, Sato S, Fujimoto M et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000;119:203-9.
Hajialilo M, Noorabadi P, Tekantapeh ST, Mahdavi AM. Endothelin-1, a-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients. Rheumatol Int 2017;37:1651-7.
Silver RM. Endothelin and scleroderma lung disease. Rheumatology (Oxford) 2008;47:25-6.
Seibold JR, Denton CP, Furst DE et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62:2101-8.
Kinikli G, Turgay M, Duman M, Ates A. Serum-soluble selectin levels in patients with rheumatoid arthritis and systemic sclerosis. Scand J Rheumatol 2004;59:315-20.
Kubo M, Ihn H, Yamane Ket al. Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis. Br J Dermatol 2000;143:392-8.
Dantas AT, Gonçalves SMC, de Almeida AR et al. Reassessing the role of the active TGF-/S1 as a biomarker in systemic sclerosis: association of serum levels with clinical manifestations. Dis Markers 2016;2016:1-6.
Saton S, Nagaoka T, Hasegawa M et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000;27:149-54.
Lambrecht S, Smith V, De Wilde K et al. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Arthritis Rheumatol 2014;66:418-27.
Gamal SM, Elgengehy FT, Kamal A et al. Growth differentiation factor-15 (GDF-15) level and relation to clinical manifestations in egyptian systemic sclerosis patients: preliminary data. Immunol Invest 2017;46:703-13.
Yanaba K, Asano Y, Tada Y et al. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. Mod Rheumatol 2012;22:668-75.
La Montagna G, D'Angelo S, Valentini G. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease. J Rheumatol 2003;30:2147-51.
Nordenbæk C, Johansen JS, Halberg P et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol 2005;34:293-7.
Muangchan C, Harding S, Khimdas S et al. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res 2012;64:1405-14.
Lis-Swiety A, Widuchowska M, Brzezińska-Wcisto L, Kucharz E. High acute phase protein levels correlate with pulmonary and skin involvement in patients with diffuse systemic sclerosis. J Int Med Res 2018;46:1634-9.
Liu X, Mayes MD, Pedroza C et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res 2013;65:1375-80.
Abdel-Magied RA, Kamel SR, Said AF et al. Serum inter-leukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement. Sarcoidosis Vasc Diffus Lung Dis 2016;33:321-30.
Tourkina E, Bonner M, Oates J et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011;4:15.
Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009;86:1111-8.
Mathai SK, Gulati M, Peng X et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010;90:812-23.
Campioni D, Monaco AL, Lanza F et al. CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis. Haematologica 2008;93:1233-7.
Fava A, Cimbro R, Wigley FM et al. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res Ther 2016;18:99
Truchetet M-E, Brembilla NC, Montanari E, Allanore Y, Chizzolini C. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011;13:R166.
Christmann RB, Wooten A, Sampaio-Barros P et al. miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res Ther 2016;18:1-13.
Makino K, Jinnin M, Kajihara I et al. Circulating miR-142-3p levels in patients with systemic sclerosis. Clin Exp Dermatol 2012;37:34-9.
Sing T, Jinnin M, Yamane Ket al. MicroRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology (Oxford) 2012;51:1550-6.
Jiang Z, Tao J-H, Zuo T et al. The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases. Scand J Rheumatol 2017;46:122-9.
Ohnishi H, Yokoyama A, Kondo Ket al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002;165:378-81.
Honda Y, KurokiY, Matsuura Eet al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995;152(6 Pt 1):1860-6.
Kohno N, Kyoizumi S, Awaya Y et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012;50:3-13.
Hu Y, Wang LS, Jin YP et al. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients. Clin Respir J 2017;11:337-45.
Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995;108:311-5.
Prasse A, Pechkovsky DV, Toews GB et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007;56:1685-93.
Prasse A, Pechkovsky DV, Toews GB et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006;173:781-92.
Denton CP, Shi-Wen X, Sutton A et al. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998;114:293-300.
Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: mCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-65.
Carulli MT, Handler C, Coghlan JG, Black CM, Denton CP. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Ann Rheum Dis 2008;67:105-9.
Antonelli A, Ferri C, Fallahi P et al. CXCL10 (a) and CCL2 (b) chemokines in systemic sclerosis-A longitudinal study. Rheumatology (Oxford) 2008;47:45-9.
Assassi S, Wu M, Tan FK et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum 2013;65:2917-27.
Bandinelli F, Del Rosso A, Gabrielli A et al. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol 2012;30:1-6.
Tiev KP, Chatenoud L, Kettaneh A et al. Augmentation de CXCL10 dans le serum au cours de la pneumopathie interstitielle de la sclerodermie systemique. Rev Med Interne 2009;30:942-6.
Bonella F, PatuzzoG, Lunardi C. Biomarker discovery in systemic sclerosis: state of the art. Curr Biomark Find 2015;5:47-68.
Ober C, Chupp GL. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immunol 2009;9:401-8.
Letuve S, Kozhich A, Arouche N et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008;181:5167-73.
Afratis NA, Selman M, Pardo A, Sagi I. Emerging insights into the role of matrix met alloproteases as therapeutic targets in fibrosis. Matrix Biol 2018;68-69:167-79.
Guiot J, Henket M, Corhay JL, Moermans C, Louis R. Sputum biomarkers in IPF: evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. PLoS One 2017;12:e0171344.
Kim W-U, Min S-Y, Cho M-L et al. Elevated matrix met alloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 2005;7:R71-9.
Shi-wen X, Kennedy L, Renzoni EAet al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007;56:4189-94.
Abraham DJ, Vancheeswaran R, Dashwood MRet al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in sclero-derma-associated fibrotic lung disease. Am J Pathol 1997;151:831-41.
Morelli S, Ferri C, Polettini E et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995;99:255-60.
Alzawawy AI, Suliman I, Hamimi A, Elsawy N, Albordiny MM. Serum soluble vascular cell adhesion molecule-1 (sVCAM-1) in scleroderma patients and its relation to pulmonary involvement and disease activity. Egypt Rheumatol 2011;33:21-6.
Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005;24:111-6.
Sedie AD, Riente L, Maggiorini L et al. Potential biomarkers in patients with systemic sclerosis. Int J Rheum Dis 2018;21:261-5.
Fernandez IE, Eickelberg O The impact of TGF-b on lung fibrosis. Proc Am Thorac Soc 2012;9:111-6.
Snowden N, Coupes B, Herrick A et al. Plasma TGF in systemic sclerosis: sectional study. Ann Rheum Dis 1994;53:763-7.
Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol 2012;2012:121439.
Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP. Circulating levels of active transforming growth factor p1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005;44:1518-24.
Jimenez SA, Castro SV, Piera-velazquez S. Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. Curr Rheumatol Rev 2010;283-94.
Zhang X, Nie S, Si X, Luo Y, Tang W. Association between the CTGF-945C/G polymorphism and systemic sclerosis: a meta-analysis. Gene 2012;509:1-6.
Tochimoto A, Kawaguchi Y, Yamanaka H. Genetic susceptibility to interstitial lung disease associated with systemic sclerosis. Clin Med Insights Circ Respir Pulm Med 2015;9:135-40.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48.
Kawaguchi Y. Contribution of interleukin-6 to the pathogenesis of systemic sclerosis. J Scleroderma Relat Disord 2017;2:6-12.
Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012;39:1120-4.
Gourh P, Arnett FC, Assassi S et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009;11:1-11.
Scala E, Pallotta S, Frezzolini A et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.
Hasegawa M, Sato S, Fujimoto M et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308-13.
Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopu-lation that mediates tissue repair. Mol Med 1994;1:71-81.
Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004;16:733-8.
Yamaguchi Y, Kuwana M. Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis. Histol Histopathol 2013;28:175-83.
Brunasso AMG, Massone C. Update on the pathogenesis of Scleroderma: focus on circulating progenitor cells. F1000Res 2016;5:723.
Boin F, De Fanis U, Bartlett SJ et al. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 2008;58:1165-74.
Rolla G, Fusaro E, Nicola S et al. Th-17 cytokines and interstitial lung involvement in systemic sclerosis. J Breath Res 2016;10:046013.
Komura K, Fujimoto M, Hasegawa M et al. Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol 2008;35:120-5.
Chen JQ, Papp G, Szodoray P, Zeher M. The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev 2016;15:1171-80.
Wuttge DM, Carlsen AL, Teku G et al. Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis. Rheumatology (Oxford) 2015;54:2100-7.
Bagnato G, Roberts WN, Roman J, Gangemi S. A systematic review of overlapping microRNA patterns in systemic sclerosis and idiopathic pulmonary fibrosis. Eur Respir Rev 2017;26:160125.
Guiot J, Struman I, Chavez V et al. Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis. Clin Epigenetics 2017;9:84.
Li Y, Huang J, Guo M, Zuo X. MicroRNAs regulating signaling pathways: potential biomarkers in systemic sclerosis. Genomics Proteomics Bioinformatics 2015;13:234-41.
Cushing L, Kuang PP, Qian J et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2011;45:287-94.
Zhou B, Zhu H, Luo H et al. MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix met alloprotei-nase 1. Biomed Pharmacother 2017;87:412-8.
Artlett CM, Sassi-Gaha S, Hope JL, Feghali-Bostwick CA, Katsikis PD. Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflam-masome-mediated collagen synthesis during fibrosis. Arthritis Res Ther 2017;19:1-8.
Deng Z, He Y, Yang X et al. MicroRNA-29: a crucial player in fibrotic disease. Mol Diagn Ther 2017;21:285-94.
Kawashita Y, Jinnin M, Makino T et al. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci 2011;61:67-9.